Our publishing team were on the ground in Orlando, Florida, for the 67th ASH Annual Meeting and Exposition, engaging directly with leading global key opinion leaders (KOLs). Through recorded in-person interviews and discussions, we produced over 400 short-form, high-impact educational videos, delivering timely, credible insights directly to healthcare professionals worldwide.
This extensive coverage reflects not only the pace and breadth of innovation presented at ASH 2025, but also the strong recognition among KOLs of the value VJHemOnc provides as a trusted, independent education platform with truly global reach.
All ASH 2025 content is now available on VJHemOnc via our dedicated ASH 2025 feature page and disease-specific channels , offering open access to the key updates and most important data from the meeting. The library of resources includes numerous insights from early-phase clinical research to real-world data to expert wrap-ups and summary discussions.
At every major congress, our editors handpick the abstracts they feel offer the most practice-changing insights or the most exciting developments.
ASH 2025 Editor Picks:
Updated results from KOMET-007: ziftomenib plus aza-ven in R/R NPM1-m or KMT2A-r AML - Amir Fathi
Updated results from RedirecTT-1: talquetamab plus teclistamab in R/R multiple myeloma with EMD - Shahzad Raza
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF - Claire Harrison
Mosunetuzumab + zanubrutinib for newly diagnosed high-burden FL: first results of MITHIC-FL2 - Lorenzo Falchi
Long-term outcomes from the Phase III IMerge trial of imetelstat in LR-MDS - Valeria Santini
